Iván R. González: A recent study has revealed crucial molecular features in phyllodes tumors of the breast
Iván R. González, Medical Oncologist at Comprehensive Oncology Center, Hospital Ángeles Puebla, shared a post on X/Twitter:
“A recent study has revealed crucial molecular features and potential therapeutic targets in phyllodes tumors (PTs) of the breast. This multi-omic profile shows that benign, borderline, and malignant fibroadenomas and PTs are genomically independent of each other. Fibroadenomas (FAs), benign PTs, borderline PTs, and malignant PTs are independent genomic entities, implying that each has a distinct mutational profile.
Mutant EGFR (c.710C > T, c.758A > G, c.1295A > G, c.2156G, >C) was identified as an interaction network center in bordering PTs, suggesting that EGFR tyrosine kinase inhibitors (EGFRi) could be an effective therapy for these tumors.
Malignant PTs exhibit a multigene comutational pattern, suggesting a synergistic effect between mutated genes in malignant processes. TP53 mutations (c.730G > T, c.844C > T, c.1019delA) are key in the molecular mechanisms underlying PT malignant behaviors. This highlights the importance of TP53 as a potential therapeutic target in malignant PTs.
The study included whole exome sequencing of 61 fibroepithelial breast tumor samples, which allowed the identification of hidden subclones with specific genetic alterations. This combined approach of genomic and transcriptomic analysis provides a deeper understanding of the relapse process and potential targeted therapy in PTs.”
- View the article attached to the post.
- Source: Iván R. González/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023